Study S000076

A Multi-center, Randomized, Double-blind, Placebo-controlled Proof of Concept Study Evaluating the Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM

ClinicalTrials.gov record

Registration

Registration: NCT06492330
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: DOUBLE
Status: COMPLETED
Enrollment: 62
Start: 2024-07-19
Primary completion: 2025-02-28
Lead sponsor: Shanghai Jiao Tong University School of Medicine
Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH); Obesity; Diabetes Mellitus, Type 2
Interventions: DRUG:CS0159; DRUG:CS0159 placebo
Results posted: FALSE

Registered primary outcomes

Percentage change in body weight relative to baseline [Baseline to 16 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.